title: Adult height in children with short stature and idiopathic delayed puberty after different management.
abstract: By retrospectively collecting data from nine Italian centres of pediatric endocrinology, we assessed the different management and final outcome of children with short stature and idiopathic delayed puberty. Data were obtained in 77 patients (54 males, 23 females) diagnosed and followed-up in the various centres during the last 15 years. Inclusion criteria were short stature at initial observation and idiopathic delayed puberty diagnosed during follow-up. At first observation, age was 13.8 +/- 1.0 years and height standard deviation score (SDS) was -2.6 +/- 0.6 in males. In females age was 13.1 +/- 0.9 years and height SDS -2.6 +/- 0.4. Local diagnostic and therapeutic protocols included testing for growth-hormone deficiency (six centres) and treatment in case of deficiency or, in the remaining centres, testosterone or no treatment in males, and no treatment in females. At diagnosis, both in males and in females, the auxological features (height SDS, target height SDS and bone age delay) were similar in the patients treated with growth hormone, testosterone or not treated. Overall 32 patients received growth hormone (25 males, 7 females), 33 no treatment (17 males, 16 females) and 12 testosterone. There was no difference in the adult height of males and females in the different treatment groups. In males there were no differences between adult and target height SDSs (growth hormone-treated 0.31 +/- 0.79, untreated 0.10 +/- 0.82, testosterone-treated 0.05 +/- 0.95), between adult and initial height SDSs (growth hormone-treated 1.70 +/- 0.93, untreated 1.55 +/- 0.92, testosterone-treated 1.53 +/- 1.43) and percentage of subjects with adult height above target height. In females, there were no differences between adult and target height SDSs (growth hormone-treated -0.49 +/- 1.13; untreated 0.10 +/- 0.97) and between adult and initial height SDSs (growth hormone-treated 1.76 +/- 0.92; untreated 1.77 +/- 0.98), whereas a significantly higher percentage of patients remained below target height in the growth hormone-treated group (6/7, 85.7% vs 5/11, 31.3%) (P = 0.02). In conclusion, the diagnostic and therapeutic management of the patients with short stature and delayed puberty is different among Italian pediatric endocrinologists. Our data do not support the usefulness of growth-hormone therapy in improving adult height in subjects with short stature and delayed puberty, particularly in the female sex.
authors: Department of Pediatrics, Azienda Ospedaliero-Universitaria di Bologna S. Orsola-Malpighi, via Massarenti 11, 40138, Bologna, Italy, zucchini@med.unibo.it.
authors: Stefano
authors: S
authors: Zucchini
authors: Malgorzata
authors: M
authors: Wasniewska
authors: Mariangela
authors: M
authors: Cisternino
authors: Mariacarolina
authors: M
authors: Salerno
authors: Lorenzo
authors: L
authors: Iughetti
authors: Mohamad
authors: M
authors: Maghnie
authors: Maria Elisabeth
authors: ME
authors: Street
authors: Manuela
authors: M
authors: Caruso-Nicoletti
authors: Stefano
authors: S
authors: Cianfarani
mesh_terms: D001827:Body Height; D005260:Female; D005500:Follow-Up Studies; D006130:Growth Disorders / Q000503:physiopathology / Q000628:therapy; D019382:Human Growth Hormone / Q000172:deficiency / Q000627:therapeutic use*; D006801:Humans; D007558:Italy; D008297:Male; D011628:Puberty, Delayed / Q000175:diagnosis / Q000188:drug therapy*; D012189:Retrospective Studies; D013739:Testosterone / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D019382:Human Growth Hormone; D013739:Testosterone
references: Eur J Pediatr. 1991 Aug;150(10):708-12
references: 1915481
references: J Clin Endocrinol Metab. 2003 Oct;88(10):4748-53
references: 14557450
references: Arch Dis Child. 1990 Oct;65(10):1109-12
references: 2248500
references: Helv Paediatr Acta. 1988 Nov;43(3):171-6
references: 3220788
references: J Clin Endocrinol Metab. 2000 Oct;85(10):3653-60
references: 11061518
references: Clin Endocrinol (Oxf). 2006 May;64(5):510-3
references: 16649968
references: Endocr Rev. 2003 Oct;24(5):668-93
references: 14570750
references: Horm Res. 2003;60 Suppl 3:35-48
references: 14671394
references: J Pediatr Endocrinol Metab. 1996 Sep-Oct;9(5):511-7
references: 8961126
references: Growth Horm IGF Res. 2004 Jun;14(3):185-94
references: 15125879
references: Acta Endocrinol (Copenh). 1992 Nov;127(5):392-6
references: 1471449
references: Eur J Clin Nutr. 2002 Feb;56(2):171-80
references: 11857051
references: J Endocrinol Invest. 2006 Jul-Aug;29(7):581-93
references: 16957405
references: Horm Res. 2006;65(4):192-6
references: 16549932
references: Horm Res. 2006;65(4):197-9
references: 16549933
references: Helv Paediatr Acta. 1987 Jun;42(1):21-8
references: 3667329
references: J Pediatr Endocrinol Metab. 2001 Jul;14 Suppl 2:953-7
references: 11529401
references: Horm Res. 1999;51 Suppl 3:101-3
references: 10592451
references: Clin Endocrinol (Oxf). 2003 Mar;58(3):267-72
references: 12608930
references: Pediatr Endocrinol Rev. 2005 Jun;2(4):645-52
references: 16208277
references: J Clin Endocrinol Metab. 1994 Feb;78(2):478-82
references: 7508951
references: J Clin Endocrinol Metab. 2000 Nov;85(11):4168-72
references: 11095449
references: J Clin Endocrinol Metab. 1995 Nov;80(11):3292-7
references: 7593441